KRMD · Koru Medical Systems, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $41.13M | $33.65M | $28.52M | $27.90M | $23.49M | $24.18M |
| Cost of Revenue | $15.52M | $12.31M | $11.81M | $12.53M | $9.72M | $9.24M |
| Gross Profit | $25.60M | $21.33M | $16.71M | $15.37M | $13.77M | $14.94M |
| R&D | $4.39M | $5.26M | $5.74M | $4.96M | $2.47M | $1.30M |
| SG&A | $23.38M | $21.63M | $20.37M | $20.61M | $17.86M | $12.03M |
| Total Operating Expenses | $28.58M | $27.78M | $26.98M | $26.15M | $20.80M | $16.19M |
| D&A | $810.5K | $888.5K | $870.4K | $587.1K | $463.1K | $418.6K |
| Operating Income | ($2.97M) | ($6.45M) | ($10.27M) | ($10.78M) | ($7.03M) | ($1.25M) |
| Interest Expense | - | - | - | - | - | - |
| Income Tax | $21.9K | $2.9K | $3.97M | ($2.01M) | $1.80M | $17.8K |
| Net Income | ($2.64M) | ($6.07M) | ($13.74M) | ($8.66M) | ($4.56M) | ($1.21M) |
| EPS - Basic | ($0.06) | ($0.13) | ($0.30) | ($0.19) | ($0.10) | ($0.03) |
| EPS - Diluted | ($0.06) | ($0.13) | ($0.30) | ($0.19) | ($0.10) | ($0.03) |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $8.87M | $9.58M | $11.48M | $17.41M | $25.33M | $27.32M |
| Accounts Receivable | $6.21M | $5.72M | $4.05M | $3.56M | $3.59M | $2.57M |
| Inventory | $3.68M | $2.80M | $3.48M | $6.40M | $6.11M | $6.83M |
| Accounts Payable | $2.27M | $1.65M | $975.2K | $2.39M | $1.23M | $624.9K |
| Current Assets | $19.99M | $19.13M | $20.26M | $29.80M | $37.32M | $37.53M |
| Total Assets | $28.20M | $27.22M | $28.46M | $42.33M | $41.29M | $39.92M |
| Current Liabilities | $8.19M | $7.20M | $4.45M | $6.96M | $4.79M | $3.67M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $11.15M | $10.40M | $8.11M | $11.01M | $4.79M | $3.76M |
| Stockholders' Equity | $17.05M | $16.81M | $20.35M | $31.33M | $36.50M | $36.16M |
| Retained Earnings | ($32.02M) | ($29.38M) | ($23.31M) | ($9.57M) | ($910.1K) | $3.65M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $462.4K | ($319.7K) | ($4.89M) | ($5.40M) | ($4.32M) | ($743.3K) |
| Investing Cash Flow | ($949.8K) | ($1.33M) | ($814.6K) | ($2.80M) | ($366.2K) | ($1.04M) |
| Financing Cash Flow | ($221.3K) | ($248.5K) | ($218.9K) | $279.5K | $2.71M | $23.22M |
| CapEx | $932.5K | $1.30M | $782.9K | $2.76M | $346.2K | $920.6K |
| Free Cash Flow | ($470.1K) | ($1.62M) | ($5.68M) | ($8.17M) | ($4.67M) | ($1.66M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 62.3% | 63.4% | 58.6% | 55.1% | 58.6% | 61.8% |
| Operating margin | -7.2% | -19.2% | -36.0% | -38.6% | -29.9% | -5.2% |
| EBITDA margin | -5.3% | -16.5% | -33.0% | -36.5% | -28.0% | -3.5% |
| Net margin | -6.4% | -18.0% | -48.2% | -31.0% | -19.4% | -5.0% |
| Free cash flow margin | -1.1% | -4.8% | -19.9% | -29.3% | -19.9% | -6.9% |
| FCF / Net income | 0.18 | 0.27 | 0.41 | 0.94 | 1.02 | 1.37 |
| R&D / Revenue | 10.7% | 15.6% | 20.1% | 17.8% | 10.5% | 5.4% |
| SG&A / Revenue | 56.8% | 64.3% | 71.4% | 73.9% | 76.0% | 49.8% |
| Effective tax rate | - | - | - | - | - | - |
| Return on assets | -9.4% | -22.3% | -48.3% | -20.5% | -11.0% | -3.0% |
| Return on equity | -15.5% | -36.1% | -67.5% | -27.6% | -12.5% | -3.4% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 2.44 | 2.66 | 4.55 | 4.28 | 7.79 | 10.24 |
| Quick ratio | 1.99 | 2.27 | 3.77 | 3.36 | 6.51 | 8.37 |
| Cash ratio | 1.08 | 1.33 | 2.58 | 2.50 | 5.29 | 7.45 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - |
| Equity multiplier | 1.65 | 1.62 | 1.40 | 1.35 | 1.13 | 1.10 |
| Liabilities / Assets | 0.40 | 0.38 | 0.28 | 0.26 | 0.12 | 0.09 |
| Efficiency | ||||||
| Asset turnover | 1.46 | 1.24 | 1.00 | 0.66 | 0.57 | 0.61 |
| Inventory turnover | 4.22 | 4.39 | 3.39 | 1.96 | 1.59 | 1.35 |
| Days sales outstanding | 55d | 62d | 52d | 47d | 56d | 39d |
| Days inventory outstanding | 86d | 83d | 108d | 187d | 229d | 270d |
| Days payable outstanding | 53d | 49d | 30d | 70d | 46d | 25d |
| Cash conversion cycle | 88d | 96d | 129d | 163d | 239d | 284d |
| Valuation | ||||||
| P / E | - | - | - | - | - | - |
| P / B | 15.7x | 10.5x | 5.5x | 5.1x | 3.6x | 7.0x |
| P / S | 6.5x | 5.2x | 3.9x | 5.8x | 5.7x | 10.4x |
| EV / EBITDA | - | - | - | - | - | - |
| Growth | ||||||
| Revenue growth (YoY) | 22.2% | 18.0% | 2.2% | 18.8% | -2.8% | 39.3% |
| Revenue CAGR (3y) | 13.8% | 12.7% | 5.7% | 17.1% | - | 25.3% |
| Revenue CAGR (5y) | 11.2% | 14.2% | - | 17.8% | - | 14.6% |
| Gross profit growth (YoY) | 20.0% | 27.7% | 8.7% | 11.6% | -7.8% | 0.6% |
| Operating income growth (YoY) | 53.9% | 37.2% | 4.7% | -53.4% | -460.2% | - |
| Net income growth (YoY) | 56.5% | 55.9% | -58.7% | -89.8% | -276.5% | - |
| EPS growth (YoY) | 53.8% | 56.7% | -57.9% | -90.0% | -233.3% | - |
| EPS CAGR (3y) | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - |
| FCF growth (YoY) | 70.9% | 71.5% | 30.5% | -75.0% | -180.4% | - |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 1.4% | -17.4% | -35.0% | -14.2% | 1.0% | 221.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Geographic
$41.13M totalUS$30.24M · 73.5%
Non Us$10.89M · 26.5%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
1.11
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Surgical & Medical Instruments & Apparatus
Comparing KORU Medical Systems against the 5 most active filers in the same SIC group.